Pediatric MEK inhibitor-associated retinopathy: 8-year experience at a tertiary academic center and report of 2 cases.

IF 1.2 4区 医学 Q3 OPHTHALMOLOGY
Jintong Liu, Rebecca G Edwards Mayhew, Lauren M Imbornoni, Jennifer L Jung, Scott C N Oliver, Nicholas K Foreman, Jean M Mulcahy Levy, Molly Hemenway, Emily A McCourt
{"title":"Pediatric MEK inhibitor-associated retinopathy: 8-year experience at a tertiary academic center and report of 2 cases.","authors":"Jintong Liu, Rebecca G Edwards Mayhew, Lauren M Imbornoni, Jennifer L Jung, Scott C N Oliver, Nicholas K Foreman, Jean M Mulcahy Levy, Molly Hemenway, Emily A McCourt","doi":"10.1016/j.jaapos.2025.104178","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>An adverse effect of mitogen-activated protein kinase (MEK) inhibitors is MEK inhibitor-associated retinopathy (MEKAR), a fluid collection between the retinal pigment epithelium (RPE) and interdigitation zone (IZ) seen in up to 90% of adults taking these medications. MEKAR is not well described in children. The purpose of this study was to characterize MEKAR screening practices, identify cases of MEKAR, and describe their clinical presentations in children.</p><p><strong>Methods: </strong>We conducted a retrospective study at our tertiary care pediatric hospital, examining pediatric patients who underwent MEK inhibitor (MEK-i) therapy between 2015 and 2023. We describe 2 cases of pediatric MEKAR that arose during the study period.</p><p><strong>Results: </strong>Of 152 patients identified, 104 met inclusion criteria. Trametinib was the most used MEK-i, with plexiform neurofibroma being the predominant indication for therapy. Optical coherence tomography macula screenings were predominantly performed in clinic, with varying screening intervals (mean, 9.85 months; median, 6.5 months). We identified 2 cases of pediatric MEKAR, both of which improved or resolved without altering MEK-i dosage. Our study suggests a lower rate of MEKAR in pediatric patients compared with adults, although limitations in screening frequency and duration may influence this observation.</p><p><strong>Conclusions: </strong>Our findings underscore the importance of systematic MEKAR screening protocols in pediatric patients receiving MEK-i therapy, facilitating early detection and monitoring of ocular toxicity. When MEKAR develops, the risks of stopping treatment must be weighed against the risks of retinopathy, although in our patients, MEKAR resolved without alterations to their medication regimen.</p>","PeriodicalId":50261,"journal":{"name":"Journal of Aapos","volume":" ","pages":"104178"},"PeriodicalIF":1.2000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Aapos","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaapos.2025.104178","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: An adverse effect of mitogen-activated protein kinase (MEK) inhibitors is MEK inhibitor-associated retinopathy (MEKAR), a fluid collection between the retinal pigment epithelium (RPE) and interdigitation zone (IZ) seen in up to 90% of adults taking these medications. MEKAR is not well described in children. The purpose of this study was to characterize MEKAR screening practices, identify cases of MEKAR, and describe their clinical presentations in children.

Methods: We conducted a retrospective study at our tertiary care pediatric hospital, examining pediatric patients who underwent MEK inhibitor (MEK-i) therapy between 2015 and 2023. We describe 2 cases of pediatric MEKAR that arose during the study period.

Results: Of 152 patients identified, 104 met inclusion criteria. Trametinib was the most used MEK-i, with plexiform neurofibroma being the predominant indication for therapy. Optical coherence tomography macula screenings were predominantly performed in clinic, with varying screening intervals (mean, 9.85 months; median, 6.5 months). We identified 2 cases of pediatric MEKAR, both of which improved or resolved without altering MEK-i dosage. Our study suggests a lower rate of MEKAR in pediatric patients compared with adults, although limitations in screening frequency and duration may influence this observation.

Conclusions: Our findings underscore the importance of systematic MEKAR screening protocols in pediatric patients receiving MEK-i therapy, facilitating early detection and monitoring of ocular toxicity. When MEKAR develops, the risks of stopping treatment must be weighed against the risks of retinopathy, although in our patients, MEKAR resolved without alterations to their medication regimen.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Aapos
Journal of Aapos 医学-小儿科
CiteScore
2.40
自引率
12.50%
发文量
159
审稿时长
55 days
期刊介绍: Journal of AAPOS presents expert information on children''s eye diseases and on strabismus as it affects all age groups. Major articles by leading experts in the field cover clinical and investigative studies, treatments, case reports, surgical techniques, descriptions of instrumentation, current concept reviews, and new diagnostic techniques. The Journal is the official publication of the American Association for Pediatric Ophthalmology and Strabismus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信